Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1972 Jul;2(1):41–44. doi: 10.1128/aac.2.1.41

Cerebrospinal Fluid Diffusion of Kanamycin in Newborn Infants

Louise L McDonald a, Joseph W St Geme Jr a
PMCID: PMC444263  PMID: 4670657

Abstract

Cerebrospinal fluid (CSF) diffusion of kanamycin was studied in 35 newborn infants. Five infants had bacterial meningitis and two had viral meningitis. One-half of the infants received an intramuscular injection of 7.5 mg of kanamycin per kg, whereas the other half received 12.5 mg/kg. Serum and CSF specimens were obtained 3 to 6 hr and 11 to 12 hr after injection. No significant difference was observed between serum levels of kanamycin after the 7.5 and 12.5 mg/kg doses at either sampling time. However, at 3 to 6 hr, in those infants without meningitis, there was a significantly higher concentration of kanamycin in the CSF after the larger 12.5 mg/kg dose. CSF levels of kanamycin did not rise to the desirable therapeutic range with either dose. We were unable to draw a definite conclusion regarding the CSF diffusion of kanamycin in bacterial meningitis, but our data suggest that complete confidence in intramuscular kanamycin in the treatment of gram-negative neonatal meningitis may not be justified, even in those cases with a brisk inflammatory response.

Full text

PDF
41

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERGER S. H., WEHRLE P. F. Kanamycin serum levels in infants and children. Ann N Y Acad Sci. 1958 Sep 30;76(2):136–139. doi: 10.1111/j.1749-6632.1958.tb54700.x. [DOI] [PubMed] [Google Scholar]
  2. BOGER W. P., GAVIN J. J. Kanamycin: its cerebrospinal fluid diffusion, renal clearance, and comparison with streptomycin. Antibiot Annu. 1958;6:677–683. [PubMed] [Google Scholar]
  3. HIGH R. H., SARRIA A., HUANG N. N. Kanamycin in the treatment of infections in infants and children. Ann N Y Acad Sci. 1958 Sep 30;76(2):289–307. doi: 10.1111/j.1749-6632.1958.tb54719.x. [DOI] [PubMed] [Google Scholar]
  4. KUNIN C. M., FINLAND M. Susceptibility and cross resistance of bacteria to streptomycin, neomycin, paromomycin, and kanamycin. Ann N Y Acad Sci. 1958 Sep 30;76(2):42–43. doi: 10.1111/j.1749-6632.1958.tb54691.x. [DOI] [PubMed] [Google Scholar]
  5. Nelson J. D. Comparative antibiotic susceptibility of organisms recovered in sepsis of the newborn. Ann N Y Acad Sci. 1966 Jun 14;132(2):1017–1019. doi: 10.1111/j.1749-6632.1966.tb43027.x. [DOI] [PubMed] [Google Scholar]
  6. RUIZ SANCHEZ F., RUIZ SANCHEZ A., NARANJO GRANDA E., WHITE A., SEAT S., BRACKEN E., KNIGHT V. Treatment of chronic amebiasis, brucellosis, and other infections with kanamycin. Antibiot Annu. 1958;6:725–735. [PubMed] [Google Scholar]
  7. Simon H. J., Axline S. G. Clinical pharmacology of kanamycin in premature infants. Ann N Y Acad Sci. 1966 Jun 14;132(2):1020–1025. doi: 10.1111/j.1749-6632.1966.tb43028.x. [DOI] [PubMed] [Google Scholar]
  8. TISCH D. E., HUFTALEN J. B., DICKISON H. L. Pharmacological studies with kanamycin. Ann N Y Acad Sci. 1958 Sep 30;76(2):44–65. doi: 10.1111/j.1749-6632.1958.tb54692.x. [DOI] [PubMed] [Google Scholar]
  9. WELCH H., WRIGHT W. W., WEINSTEIN H. I., STAFFA A. W. In vitro and pharmacological studies with kanamycin. Ann N Y Acad Sci. 1958 Sep 30;76(2):66–80. doi: 10.1111/j.1749-6632.1958.tb54693.x. [DOI] [PubMed] [Google Scholar]
  10. YOW M. D., TENGG N. E. The use of kanamycin sulfate as a therapeutic agent for infants and children. An analysis of 140 cases treated during a two-year period. J Pediatr. 1961 Apr;58:538–547. doi: 10.1016/s0022-3476(61)80189-3. [DOI] [PubMed] [Google Scholar]
  11. YOW M. D., YOW E. M. Kanamycin, neomycin and paromomycin. Pediatr Clin North Am. 1961 Nov;8:1043–1056. doi: 10.1016/s0031-3955(16)31192-0. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES